Voyager Therapeutics Inc.
02/12/2026 | Press release | Distributed by Public on 02/12/2026 07:01
Management Change/Compensation (Form 8-K)
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Resignation of Chief Medical Officer
On February 9, 2026, Toby Ferguson, M.D., Ph.D. notified Voyager Therapeutics, Inc. (the "Company") of his decision to resign from his position as Chief Medical Officer of the Company and from any and all other positions he holds with the Company and any of its subsidiaries, effective February 20, 2026, to pursue a new opportunity. Dr. Ferguson's resignation is not a result of any disagreement with the Company.
| Item 8.01 |
Other Events. |
Alfred W. Sandrock, Jr., M.D., Ph.D., the Company's current President and Chief Executive Officer, has agreed to assume key responsibilities, including strategic guidance for the Company's clinical development programs, on an interim basis following the effective date of Dr. Ferguson's resignation.
Voyager Therapeutics Inc. published this content on February 12, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 12, 2026 at 13:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]